COGT Cogent Corp: Accounting Value per Share

This daily price chart for Cogent Biosciences (COGT) demonstrates volatility, with the current indicator standing at 2.73. The biotech's financial stability remains uncertain, as a lack of sales leaves the company dependent on grants and test results. Meanwhile, the business aims to secure leadership in mastocytosis treatment by bringing bezroklinib to market, leveraging patent protection and high FDA certification costs.

Cogent Bio - COGT Net Assets per Share (period 07/04/2022 - 10/28/2026)

Summary analytical data breakdowns for cogentbio.com (COGT)

- price and consensus price forecast:

Stock Price Cogent Bio|COGT - Analyst Target Range

- market capitalization data:

Market Valuation Cogent Biosciences, Inc.|COGT - Aggregate Business Value

- book capitalization data:

Net Assets per Single Share Cogent Biosciences|COGT - Book Valuation of Business|Market Value to Book Value Ratio cogentbio.com|COGT - Total Asset Value of Company

- debt and liquidity data:

Total Debt to Capital Cogent Biosciences|COGT - Long-Term Liabilities to Capital|Short-Term Debt to Capital Cogent Biosciences, Inc.|COGT - Company Total Debt|Debts to Book Capitalization Cogent Biosciences, Inc.

Analysis of all company metrics:Cogent Bio COGT

For the biotech sector, Cogent Biosciences (COGT) financial stability determines the timeline for clinical trial execution. This metric is calculated as the difference between total assets and liabilities, divided by the number of shares. An analysis of the net book value per share allows for an assessment of the company's internal capital reserve. The stability of this metric confirms fund confidence in management's scientific expertise. High coverage minimizes default risks during long-term drug development.

Competitors of Cogent Biosciences (COGT)